Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biodegradable tissue replacement implant and its use

a tissue replacement and biodegradable technology, applied in the field of cell-based therapies, can solve problems such as serious vision loss

Pending Publication Date: 2022-01-20
UNITED STATES OF AMERICA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a method for making a tissue replacement implant for the eye by using a scaffold made of poly(lactic-co-glycolic acid) (PLGA) and retinal pigment epithelial cells. The PLGA scaffold is fused with heat to increase its strength and reduce pore size. The cells are then seeded onto the scaffold and cultured in a special medium to polarize the cells and degrade the PLGA scaffold. The resulting tissue replacement implant can be used to treat retinal degenerative diseases, retinal damage, or loss of retinal pigment epithelium. The technical effects include improved mechanical strength and reduced pore size of the PLGA scaffold, as well as polarization of the cells and degradation of the scaffold.

Problems solved by technology

Both conditions lead to photoreceptor cell death, causing serious vision loss and can lead to blindness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biodegradable tissue replacement implant and its use
  • Biodegradable tissue replacement implant and its use
  • Biodegradable tissue replacement implant and its use

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

Research and Clinical-Grade iPSC Derivation, Maintenance, and RPE Differentiation

[0231]Reporter iPSC line expressing GFP under the control of TYROSINASE enhancer and constitutive RFP was previously published (Maruotti et al., Proc Natl Acad Sci USA 112, 10950-10955 (2015)) and used to optimize the research-grade differentiation protocol. iPSCs were cultured on MEFs for 4 days before using for differentiation. To make cell aggregates, iPSCs were treated with Collagenase for 20 mins. After collagenase was aspirated, NEIM (DMEM / F12, KOSR, supplemented with N2, B27, LDN-193189 10 uM, SB431452 10 nM, CKI-7 hydrochloride 0.5 uM, and IGF-1 1 ng / ml) was added to the wells (1 ml / well) and cell scarper was used to scrape the colonies. Cell aggregates were grown in 10 cm2 low attachment corning dishes in NEIM medium for 48 hrs. After 48 hours, floating cell aggregates were collected and seeded in MATRIGEL® coated plates in RPEIM (DMEM / F12, KOSR, supplemented with N2, B27, ...

example 2

Clinical-Grade Triphasic Protocol Efficiently and Reproducibly Generates AMD-iRPE Cells

[0252]iPSC-derived from AMD-patient skin fibroblasts under clinical-grade conditions attained chromosomal copy number changes, likely during the reprograming process (Mandai et al., N Engl J Med 376, 1038-1046 (2017)). However, skin fibroblasts are not considered an ideal starting source when deriving iPSCs from older patients (Kang et al., Cell Stem Cell 18, 625-636 (2016)). Therefore, a manufacturing workflow was developed for autologous iPSC-derived RPE-patch from patient CD34+ peripheral blood cells. A pipeline for generation, functional validation, and in vivo testing of clinical-grade AMD patient-specific iPSC-RPE patch (FIGS. 1A, B) was developed. Due to the progenitor and proliferative nature, CD34+ cells isolated from patients' peripheral blood could provide a good source for iPSC generation. Multiple iPSC clones were generated from CD34+ cells and skin fibroblasts of three advanced “dry”...

example 3

Biodegradable Scaffold Helps Clinical-Grade AMD-iRPE Cells to Functionally Mature into a Monolayer Tissue

[0256]It was hypothesized that a biodegradable scaffold would provide suitable material for RPE cells to secrete extracellular matrix (ECM) to form a polarized monolayer. As the scaffold degrades, ECM and cells would constitute a native-like RPE tissue that would enhance the possibility of long-term integration of iRPE-patch in patients' eyes. Scaffolds used in the clinical-grade process were manufactured using poly-(lactic-co-glycolic acid) / PLGA (50:50 lactic acid / glycolic acid, IV midpoint 1.0 dl / g), with 350 nm mean fiber diameter previously shown to be optimal for RPE growth (Liu, et al., Biomaterials 35, 2837-2850 (2014); Stanzel et al., Stem Cell Reports 2, 64-77 (2014)). A single layer heat-fused nanofibers scaffold was selected for iRPE-patch manufacturing because of its high Young's Modulus that correlated with the ease of transplantation (FIGS. 2A, 2B). As expected for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
pore sizeaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

Tissue replacement implants are disclosed that include polarized retinal pigment epithelial cells on a polylactic-co-glycolic acid) (PLGA) scaffold, wherein the PLGA scaffold is 20-30 microns in thickness, has a DL-lactide / glycotide ratio of about 1:1, an average pore size of less than about 1 micron, and a fiber diameter of about 150 to about 650 nm. Also disclosed are methods of treating a subject with a retinal degenerative disease, retinal or retinal pigment epithelium dysfunction, retinal degradation, retinal damage, or loss of retinal pigment epithelium. These methods include locally administering to the eye of the subject the tissue replacement implant. In further embodiments, methods are disclosed for producing the tissue replacement implant.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This claims the benefit of U.S. Provisional Application No. 62 / 769,484, filed Nov. 19, 2018, which is incorporated by reference herein.STATEMENT OF GOVERNMENT SUPPORT[0002]This invention was made with government support under project no. ZA1#: ET000542-03 awarded by the National Institutes of Health, the National Eye Institute. The government has certain rights in the invention.FIELD OF THE DISCLOSURE[0003]This disclosure is related to the field of cell-based therapeutics, specifically to tissue replacement implants including retinal pigment epithelium (RPE) cells, and methods for producing and using these tissue replacement implants.BACKGROUND[0004]Cell-based therapeutics offer the promise of ‘permanent’ replacement of degenerative tissue. The eye is an appealing area of interest due to its ease of accessibility and the urgent need for effective therapies to help a growing elderly population experiencing vision loss (Fischbach, et al., S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61L27/38A61L27/18A61L27/54A61L27/56
CPCA61L27/3813A61L27/18A61L27/3834A61L2430/16A61L27/54A61L27/56A61L27/3869A61L27/3804A61L27/227A61L27/58C08L67/04A61F9/0017
Inventor MANINISHKIS, ARVYDASBHARTI, KAPIL
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com